LY3457263 + Tirzepatide for Obesity

Phase-Based Progress Estimates
LabCorp CRU, Inc., Daytona Beach, FLObesity+1 MoreTirzepatide - Drug
20 - 70
All Sexes
What conditions do you have?

Study Summary

This trial will assess the safety and tolerability of a new drug combo in overweight/obese participants, and measure how much of the drug gets into their bloodstream. It will last 11 weeks.

Eligible Conditions
  • Obesity

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Predose on Day 1 up to 43 days postdose

Week 11
Therapeutic procedure
Day 43
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3457263

Trial Safety

Trial Design

2 Treatment Groups

LY3457263 + Tirzepatide
1 of 2
Placebo + Tirzepatide
1 of 2

Experimental Treatment

Non-Treatment Group

45 Total Participants · 2 Treatment Groups

Primary Treatment: LY3457263 + Tirzepatide · Has Placebo Group · Phase 1

LY3457263 + TirzepatideExperimental Group · 2 Interventions: Tirzepatide, LY3457263 · Intervention Types: Drug, Drug
Placebo + TirzepatidePlaceboComparator Group · 2 Interventions: Tirzepatide, Placebo · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Completed Phase 1

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: predose on day 1 up to 43 days postdose

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,479 Previous Clinical Trials
3,139,488 Total Patients Enrolled
27 Trials studying Obesity
24,023 Patients Enrolled for Obesity
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)Study DirectorEli Lilly and Company
1,266 Previous Clinical Trials
371,073 Total Patients Enrolled
17 Trials studying Obesity
7,278 Patients Enrolled for Obesity

Eligibility Criteria

Age 20 - 70 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your weight and body mass index (BMI) fall within the range of 27.0 to 45.0 kilograms per meter squared (kg/m²).

Who else is applying?

What state do they live in?
New York100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%

Frequently Asked Questions

Is participation in this research open to me?

"In order to be considered for this study, individuals must demonstrate obesity and fall within the 20-70 year old age bracket. There are 45 spots available in total." - Anonymous Online Contributor

Unverified Answer

Are there still openings for people to join this clinical trial?

"Affirmative. presents evidence that this clinical research project, which was initially posted on November 11th 2022, is presently seeking enrollees. Approximately 45 patients need to be enrolled across a single medical centre." - Anonymous Online Contributor

Unverified Answer

Has the combination of LY3457263 and Tirzepatide obtained regulatory approval?

"As LY3457263 + Tirzepatide is still undergoing its initial trial, there are only a few data points that can serve as evidence of the drug's safety and efficacy. Thus, our team at Power rates it a 1 on their scale from 1 to 3." - Anonymous Online Contributor

Unverified Answer

Does this experimental study recruit individuals over the age of 40?

"Qualified participants of this experiment must span the ages 20 to 70 inclusive. There are 223 studies open for individuals below the age of majority, and 697 trials available for those over 65 years old." - Anonymous Online Contributor

Unverified Answer

How many patients are enrolled in this research trial at its current capacity?

"Affirmative. The information available on confirms that the trial commenced recruitment on November 11th 2022 and is still ongoing, requiring 45 participants from one location." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.